Neuro

For founders pursuing commercial opportunities in the neuroscience space.

  • All Ventures
  • CDL-Toronto

Sinaptica Therapeutics

Sinaptica Therapeutics has developed SinaptiStim™, a personalized rTMS (repetitive Transcranial Magnetic Stimulation)  neuromodulation system delivering non-invasive, ML-driven neurostimulation to enhance neuroplasticity in key brain networks to slow the progression of Alzheimer's. Current treatments for Alzheimer’s are minimally effective in delaying cognitive decline, are burdened by IV infusions, brain bleeding/swelling, and require costly MRI monitoring. Sinaptica addresses this by targeting the Default Mode Network (DMN), an area of the brain related to episodic memory,  using a novel approach that enhances neuroplasticity via neurostimulation, offering a safer and more cost-effective alternative for treating Alzheimer’s than invasive anti-amyloid drugs and other non-invasive brain stimulation methods. Sinaptica has been granted FDA Breakthrough Designation for their SinaptiStimTM system. 

sinapticatx.com

CDL Mentor Endorsement
"The founders created an technology that tailors and targets transcranial magnetic stimulation, through a personalized medicine approach, that slows the advancement of Alzheimer's Disease symptoms, a disease that is riddled with many therapeutic failures or minimally effective treatments. As a mentor who has participated in the development of neuromodulation therapies, I saw high potential for a non invasive, non pharmacologic therapy that has pilot data signaling a potential significant impact on preventing disease symptom worsening. Equally important, the product received FDA breakthrough status which may accelerate the regulatory pathway. The team is dynamic and fast paced. They have a can do attitude. However, at times this strength was a weakness where the founders did not explore/consider alternative development pathways as well had blind spots to market adoption barriers. The leadership team was perhaps over enthusiastic about the preliminary data. While encouraging it was a single center study conducted by the inventor. During the first mentoring session, the founders pivoted from a number of preconceived view points effectively receiving mentor input and became open to alternative approaches to address clinical development, business model challenges, and barriers to market adoption. This was an inflection point which propelled the team effectively addressing challenging barriers.   The company has great potential. The product is novel and non invasive addressing a very large unmet need. The founders are energic, highly coachable and demonstrated a 'get stuff done' culture."   - Michael Ujhelyi, Health Economics and Outcomes Consultant, Medtronic

Lantern Laboratory Inc

Lantern Laboratory has developed an intraoperative brain monitor that uses proprietary algorithms to analyze EEG signals in real time, optimizing anesthesia care. Anesthesia dosing is currently subjective, and incorrect dosing can lead to serious consequences, such as postoperative delirium, long-term cognitive decline, and increased mortality. Lantern’s brain monitor provides real-time, patient-specific data on cognitive age and pain perception (nociception) independent of sedation, capabilities not currently offered by any FDA-cleared device, to optimize analgesia and sedation and reduce postoperative complications. What sets Lantern apart is its integration of data from over 2,000 surgeries at Columbia University and the team’s expertise in surgical and computational neuroscience.

lanternlaboratory.com

CDL Mentor Endorsement
"I raised my hand for Lantern Laboratory because they’re addressing a critical blind spot in surgical care: ensuring patients are adequately sedated and receiving the right level of analgesia, without tipping into oversedation that can contribute to post-operative complications like delirium. Their solution bridges a gap between monitoring and meaning—transforming raw physiologic signals into clear, actionable insights for anesthesiologists and surgical teams. Delirium is a devastating and under-recognized post-operative complication, especially among older adults, and avoiding it requires nuanced control of sedation and pain management—something that’s currently far too dependent on subjective judgment and fragmented data. Lantern’s tool promises to bring a level of clarity and control to the OR that simply doesn’t exist today. It’s a focused, elegant intervention that could have wide-ranging impact on surgical outcomes, patient recovery, and overall healthcare costs."  - Imran Eba, Partner, Action Potential Venture Capital Ltd

Neuralenz

Neuralenz has developed a non-invasive, photonics device that continuously and quantitatively measures cerebral blood flow and intracranial pressure, targeting neurocritical care applications such as stroke, traumatic brain injury, and dementia. Currently, Neurologists rely on continuous data obtained from invasive intracranial sensors to diagnose and manage interventions for neurocritical care patients. Neuralenz can obtain the same data with a non-invasive device using advanced optical and machine learning technologies, providing highly specific brain signal measurements with superior accuracy and cost-efficiency while reducing patient risk by avoiding invasive procedures.  

neuralenz.com

CDL Mentor Endorsement
"Oybek is a bright and capable entrepreneur advancing important technology in the Neurocritical Care space. He combines curiosity and collaboration with a commitment to continuous learning, while knowing when to firmly stand by his groung when necessary. His ability to maintain momentum and manage complex situations gives me confidence in his continued success going forward." - Lahav Gil, CEO and Chairperson, Arma Biosciences

Canurta Therapeutics

Canurta Therapeutics is a biotech company that has developed a proprietary platform that can produce high-purity botanical compounds for neurodegenerative disease treatments, particularly ALS. Current treatments for ALS often target only a single pathway, leaving patients with limited solutions. Canurta’s CNR 401, derived from rare botanical sources like cannflavins, provides a more comprehensive multi-pathway treatment. The venture’s ML-powered platform enables the efficient extraction, design, and testing of these rare molecules. Canurta leverages cutting-edge research from the University of Guelph and is backed by a team with proven success in bringing botanical drugs to market, which will help position the company well for regulatory approval and market traction.

canurta.com

CDL Mentor Endorsement

Neuradaptive

Neuradaptive is developing an adaptive neuromodulation device designed to stimulate neural circuits involved in learning and memory, initially targeting stroke and traumatic brain injury (TBI) recovery. Their device integrates precisely timed deep brain stimulation with personalized, AI-enabled behavioral training, offering a more targeted and effective alternative to existing therapies for neurological conditions. This approach not only accelerates cognitive recovery for stroke and TBI but also holds the potential for inducing durable neuroplasticity and slowing the progression of neurodegenerative diseases. 

Other Streams